36 results on '"Luo, Hongtao"'
Search Results
2. Cold sintering preparation of B4C@SiO2/20BP ceramic matrix composite and its dry tribological properties
- Author
-
Gu, Dapeng, Wang, Guanqun, Yang, Bingchao, Luo, Hongtao, Chen, Suwen, and Xu, Hao
- Published
- 2024
- Full Text
- View/download PDF
3. Stereotactic Puncture Surgery for the Treatment of Moderate Volume of Thalamus-Internal Capsule Area Hemorrhage: An Analysis of Real-World Data
- Author
-
Yang, Shiqiang, Liu, Yanwei, Wang, Shiqiang, Peng, Hua, Luo, Hongtao, Cai, Zhonghai, Hui, Xuhui, and Yang, Anqiang
- Published
- 2024
- Full Text
- View/download PDF
4. Si3N4@SiO2/PEEK core-shell structure ceramic matrix composite prepared by cold sintering and its tribological properties
- Author
-
Gu, Dapeng, Wang, Guanqun, Chen, Suwen, Luo, Hongtao, Chen, Xiaofan, and Liu, Ziyu
- Published
- 2024
- Full Text
- View/download PDF
5. Regulatory role of RGMb in lung injury promoted by the combination of carbon ion irradiation and anti-PD-1 antibody through Erk1/2 and p38 MAPK pathways
- Author
-
Feng, Shuangwu, Luo, Hongtao, Li, Chengcheng, Geng, Yichao, Yang, Zhen, Zhao, Xueshan, Wang, Lina, Liu, Ruifeng, Zhang, Yanying, Che, Tuanjie, Zhang, Qiuning, and Wang, Xiaohu
- Published
- 2024
- Full Text
- View/download PDF
6. A pancancer analysis of the carcinogenic role of receptor-interacting serine/threonine protein kinase-2 (RIPK2) in human tumours
- Author
-
Zhang, Hanqun, Ma, Yan, Zhang, Qiuning, Liu, Ruifeng, Luo, Hongtao, and Wang, Xiaohu
- Published
- 2022
- Full Text
- View/download PDF
7. Loss of RPS27a expression regulates the cell cycle, apoptosis, and proliferation via the RPL11-MDM2-p53 pathway in lung adenocarcinoma cells
- Author
-
Li, Hongyan, Zhang, Hong, Huang, Guomin, Bing, Zhitong, Xu, Duling, Liu, Jiadi, Luo, Hongtao, and An, Xiaoli
- Published
- 2022
- Full Text
- View/download PDF
8. Assessing the Impact of Charged Particle Radiation Therapy for Head and Neck Adenoid Cystic Carcinoma: A Systematic Review and Meta-Analysis.
- Author
-
Tan, Mingyu, Chen, Yanliang, Du, Tianqi, Wang, Qian, Wu, Xun, Zhang, Qiuning, Luo, Hongtao, Liu, Zhiqiang, Sun, Shilong, Yang, Kehu, Tian, Jinhui, and Wang, Xiaohu
- Subjects
ADENOID cystic carcinoma ,PROTON beams ,RADIOTHERAPY ,NECK ,PROTON therapy ,OVERALL survival ,PROGRESSION-free survival - Abstract
Purpose: Head and neck adenoid cystic carcinoma (HNACC) is a radioresistant tumor. Particle therapy, primarily proton beam therapy and carbon-ion radiation, is a potential radiotherapy treatment for radioresistant malignancies. This study aims to conduct a meta-analysis to evaluate the impact of charged particle radiation therapy on HNACC. Methods: A comprehensive search was conducted in Pubmed, Cochrane Library, Web of Science, Embase, and Medline until December 31, 2022. The primary endpoints were overall survival (OS), local control (LC), and progression-free survival (PFS), while secondary outcomes included treatment-related toxicity. Version 17.0 of STATA was used for all analyses. Results: A total of 14 studies, involving 1297 patients, were included in the analysis. The pooled 5-year OS and PFS rates for primary HNACC were 78% (95% confidence interval [CI] = 66-91%) and 62% (95% CI = 47-77%), respectively. For all patients included, the pooled 2-year and 5-year OS, LC, and PFS rates were as follows: 86.1% (95% CI = 95-100%) and 77% (95% CI = 73-82%), 92% (95% CI = 84-100%) and 73% (95% CI = 61-85%), and 76% (95% CI = 68-84%) and 55% (95% CI = 48-62%), respectively. The rates of grade 3 and above acute toxicity were 22% (95% CI = 13-32%), while late toxicity rates were 8% (95% CI = 3-13%). Conclusions: Particle therapy has the potential to improve treatment outcomes and raise the quality of life for HNACC patients. However, further research and optimization are needed due to the limited availability and cost considerations associated with this treatment modality. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Investigation on regenerative heat exchanger with novel low-leakage system for flue gas denitration in steel industry
- Author
-
Wang, Limin, Li, Dechao, Zhu, Hua, Chen, Guozhong, Luo, Hongtao, and Che, Defu
- Published
- 2020
- Full Text
- View/download PDF
10. Safety and Efficacy of Carbon Ion and Proton Therapies for Pancreatic Cancer: A Systematic Review and Meta-analysis
- Author
-
LIAO Yiran, ZHANG Qiuning, SHAO Lihua, LIU Ruifeng, LUO Hongtao, WANG Lina, FENG Shuangwu, YANG Kehu, and WANG Xiaohu
- Subjects
carbon ion ,proton ,pancreatic cancer ,systematic review ,meta-analysis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Objective To evaluate the safety and efficacy of carbon ion and proton therapies for pancreatic cancer (PaC). Methods The databases were electronically searched to collect the studies about the carbon ion and proton therapies for PaC from inception to June 2019. Two reviewers independently screened literature and extracted data. A Meta-analysis was performed by STATA 12.0 and MetaAnalyst Beta 3.13 software. Results A total of 8 studies involving 459 PaC patients were included. The incidence of grade 2, 3 and 5 gastrointestinal (GI) ulcer toxicities in PaC patients treated with carbon ion and proton therapies were 7%, 2% and 0; the incidence of grade 2, 3 and 4 anorexia toxicities were 6%, 3.2% and 0; the 1- and 2-year OS rates were 77% and 45%; the 2-year local control (LC), 1-year freedom from local progression (FFLP) and 1-year local recurrence(LR) rates were 81%, 88% and 15%. The incidence of grade 2, 3, 2-3 GI ulcer toxicities in carbon ion and proton therapies for PaC were 6.8%, 1.5%, 9.2% and 3.5%, 8.3%, 6.1% (P < 0.05); and the 1- and 2-year OS were 77.1%, 44.4% and 77.6%, 49.7% (P > 0.05). Conclusion Carbon ion and proton therapies for PaC are safe and effective; and the security and effectiveness of the two methods are similar.
- Published
- 2020
- Full Text
- View/download PDF
11. Carbonions and Proton Therapy for Hepatocellular Carcinoma: A Meta-analysis
- Author
-
SHAO Lihua, ZHANG Qiuning, LUO Hongtao, YANG Zhen, LIU Ruifeng, TIAN Jinhui, LI Zheng, WANG Xiaohu, and YANG Kehu
- Subjects
hepatocellular carcinoma ,carbon ion ,proton ,meta-analysis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Objective To evaluate the efficacy and safety of carbon ion and proton therapy for hepatocellular carcinoma (HCC) by Meta-analysis. Methods PubMed, The Cochrane Library, EMBASE, Chinese Journal Full-text, Chinese Biomedical Literature and Wanfang Database were searched to collect relevant clinical studies on carbon ion and proton therapy for HCC. Two reviewers independently screened the literature and extracted data based on inclusion and exclusion criteria. Meta-analysis was carried out by Stata 12.0. Results We included 7 carbon ion and 23 proton therapy studies. According to the combined results, both carbon ion and proton therapies for HCC obtained good local control rate and low adverse reactions, and the incidence of severe adverse reactions was low. Subgroup analysis showed that carbon ion and proton therapies improved the 5-year OS of HCC patients with either favorable or poor prognosis. Conclusion Both carbon ion and proton therapies may be the effective alternative treatment options for HCC with favorable prognosis, and also show better efficacy for HCC patients with poor prognosis.
- Published
- 2020
- Full Text
- View/download PDF
12. Silencing of the lncRNA H19 enhances sensitivity to X-ray and carbon-ions through the miR-130a-3p /WNK3 signaling axis in NSCLC cells
- Author
-
Zhao, Xueshan, Jin, Xiaodong, Zhang, Qiuning, Liu, Ruifeng, Luo, Hongtao, Yang, Zhen, Geng, Yichao, Feng, Shuangwu, Li, Chengcheng, Wang, Lina, Wang, Xiaohu, and Li, Qiang
- Published
- 2021
- Full Text
- View/download PDF
13. Propargylic Dialkyl Effect for Cyclobutene Formation through Ir(III)-Catalyzed Cycloisomerization of 1,6-Enynes.
- Author
-
Zhu, Xuanyu, Li, Yi, Luo, Hongtao, Li, Jing, Hua, Yuhui, Liu, Guohua, Li, Lingling, and Liu, Rui
- Published
- 2024
- Full Text
- View/download PDF
14. Influence of Different Radio-chemotherapy Modes for Incidence of Radiation Pneumonitis in Patients with Lung Cancer
- Author
-
LIU Ruifeng, WEI Shihong, ZHANG Qiuning, LUO Hongtao, DONG Yumei, and WANG Xiaohu
- Subjects
radiotherapy ,chemotherapy ,pulmonary malignant tumor ,radiation pneumonitis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Objective To compare the difference of different radio-chemotherapy modes and clinical characters for more than grade 2 radiation pneumonitis (RP) incidence in patients with lung cancer. Methods We retrospectively analyzed the 136 patients with lung cancer who were treated with radio-chemotherapy in our hospital from January 2014 to January 2016. Following-up was undergone regularly after treatment. RTOG standard of acute radiation pneumonia was applied to evaluate lung injury grade. We also analyzed the effect of clinical character and treatment modes on RP. Results There were 36 cases diagnosed as ≥grade 2 RP, and the occurrence rate was 26.5%. The patients with dust exposure history(P=0.048) and NSCLC pathology type (P=0.047) had a higher RP incidence, while other characters had no statistical difference. Comparing between concomitant chemoradiation group and sequential chemoradiation group, there was statistical difference in the incidence of ≥grade 4 RP (6.7% vs. 0, P=0.05), however, no statistical difference in overall RP, grade 2 or grade 3 RP. There was no statistical difference among different chemotherapy regimens to ≥grade 2 RP. There was significantly positive correlation of RP severity with the total chemotherapy cycles or induction chemotherapy cycles(P=0.000). Conclusion Dust exposure history and pathology type are two clinical character factors to influence the incidence of RP. RP is closely related to the chemotherapy cycles, especially in total chemotherapy cycles or induction chemotherapy cycles.
- Published
- 2018
- Full Text
- View/download PDF
15. Efficacy and safety of carbon ion radiotherapy for chordomas: a systematic review and meta-analysis.
- Author
-
Dong, Meng, Liu, Ruifeng, Zhang, Qiuning, Wang, Dandan, Luo, Hongtao, Wang, Yuhang, Chen, Junru, Ou, Yuhong, and Wang, Xiaohu
- Subjects
SKULL base ,RADIOTHERAPY ,CARBON ,OVERALL survival ,DATABASE searching - Abstract
Objective: Carbon ion radiotherapy (C-ion RT) for chordomas has been gradually performed in several research centres. This study aimed to systematically review the results of clinical reports from these institutions and to evaluate the safety and efficacy of C-ion RT. Methods: In accordance with the PRISMA guidelines and set search strategies, we searched four databases for articles from their inception to February 11, 2023. These articles were screened, and data were extracted independently by two researchers. STATA 14.0 was used for statistical analysis of survival results. Results: A total of 942 related articles were retrieved, 11 of which were included. Regarding lesion location, 57% (n = 552) originated in the sacral region, 41% (n = 398) in the skull base, and 2% (n = 19) in the spine (upper cervical). The local control (LC) rates at 1, 2, 3, 5, 9, and 10 years in these studies were 96%, 93%, 83%, 76%, 71%, and 54%, respectively. The overall survival (OS) rates at 1, 2, 3, 5, 9, and 10 years in these studies were 99%, 100%, 93%, 85%, 76%, and 69%, respectively. Acute and late toxicities were acceptable, acute toxicities were mainly grade 1 to grade 2 and late toxicities were mainly grade 1 to grade 3. Conclusion: C-ion RT has attractive clinical application prospects and is an important local treatment strategy for chordomas. Encouraging results were observed in terms of LC and OS. Meanwhile, the acute and late toxicities were acceptable. PROSPERO registration number: CRD42023398792. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Carbon Ions Suppress Angiogenesis and Lung Metastases in Melanoma by Targeting CXCL10.
- Author
-
Li, Chengcheng, Zhang, Qiuning, Luo, Hongtao, Liu, Ruifeng, Feng, Shuangwu, Geng, Yichao, Wang, Lina, Yang, Zhen, Zhang, Yanying, and Wang, Xiaohu
- Subjects
LUNGS ,CHEMOKINES ,ENZYME-linked immunosorbent assay ,X-rays ,IONS ,METASTASIS - Abstract
Carbon-ion radiotherapy (CIRT) enhanced local control in patients with malignant melanoma. In several in vitro studies, carbon ions (C ions) have been also shown to decrease the metastatic potential of melanoma cells. CXC motif 10 (CXCL10) has been shown to play a crucial role in regulating tumor metastasis and it significantly increase in human embryonic kidney cells after heavy ion irradiations. This study sought to explore the regulatory effect of C ions on melanoma metastasis, emphasizing the role of CXCL10 in this process. To explore the potential regulatory effect of C ions on tumor metastasis in vivo, we developed a lung metastasis mouse model by injecting B16F10 cells into the footpad and subjected all mice to treatment with X rays and C ions. Subsequently, a series of assays, including histopathological analysis, enzyme-linked immunosorbent assay, real-time PCR, and western blotting, were conducted to assess the regulatory effects of C ions on melanoma. Our results showed that mice treated with C ions exhibited significantly less tumor vascularity, enhanced tumor necrosis, alleviated lung metastasis, and experienced longer survival than X-ray irradiated mice. Moreover, VEGF expression in B16F10 cells was significantly reduced by C-ion treatment, which could be alleviated by CXCL10 knockdown in vitro. Further investigations revealed that co-culturing with HUVECs resulted in a significant inhibition of proliferation, migration, and tube formation ability in the C-ion treated group, while the opposite effect was observed in the C-ion treated with si-CXCL10 group. In conclusion, our findings demonstrate that treatment with carbon-ion radiation can suppress angiogenesis and lung metastases in melanoma by specifically targeting CXCL10. These results suggest the potential utility of carbon ions in treating melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Biological effects of cancer stem cells irradiated by charged particle: a systematic review of in vitro studies.
- Author
-
Wang, Qian, Liu, Ruifeng, Zhang, Qiuning, Luo, Hongtao, Wu, Xun, Du, Tianqi, Chen, Yanliang, Tan, Mingyu, Liu, Zhiqiang, Sun, Shilong, Yang, Kehu, Tian, Jinhui, and Wang, Xiaohu
- Subjects
CANCER stem cells ,DOUBLE-strand DNA breaks ,IN vitro studies ,DNA repair ,DNA damage - Abstract
Purpose: The existence of cancer stem cells (CSCs) is closely related to tumor recurrence, metastasis, and resistance to chemoradiotherapy. In addition, given the unique physical and biological advantages of charged particle, we hypothesized that charged particle irradiation would produce strong killing effects on CSCs. The purpose of our systematic review is to evaluate the biological effects of CSCs irradiated by charged particle, including proliferation, invasion, migration, and changes in the molecular level. Methods: We searched PubMed, EMBASE, and Web of Science until 17 march 2022 according to the key words. Included studies have to be vitro studies of CSCs irradiated by charged particle. Outcomes included one or more of radiation sensitivity, proliferation, metastasis, invasion, and molecular level changes, like DNA damage after been irradiated. Results: Eighteen studies were included in the final analysis. The 18 articles include 12-carbon ion irradiation, 4-proton irradiation, 1 α-particle irradiation, 1-carbon ion combine proton irradiation. Conclusion: Through the extraction and analysis of data, we came to this conclusion: CSCs have obvious radio-resistance compared with non-CSCs, and charged particle irradiation or in combination with drugs could overcome this resistance, specifically manifested in inhibiting CSCs' proliferation, invasion, migration, and causing more and harder to repair DNA double-stranded breaks (DSB) of CSCs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis.
- Author
-
Chen, Yanliang, Luo, Hongtao, Liu, Ruifeng, Tan, Mingyu, Wang, Qian, Wu, Xun, Du, Tianqi, Liu, Zhiqiang, Sun, Shilong, Zhang, Qiuning, and Wang, Xiaohu
- Subjects
- *
NON-small-cell lung carcinoma , *PROTON therapy - Abstract
Background and purpose: Particle therapy, mainly including carbon-ion radiotherapy (CIRT) and proton beam therapy (PBT), has dose distribution advantages compared to photon radiotherapy. It has been widely reported as a promising treatment method for early non-small cell lung cancer (NSCLC). However, its application in locally advanced non-small cell lung cancer (LA-NSCLC) is relatively rare, and its efficacy and safety are inconclusive. This study aimed to provide systematic evidence for evaluating the efficacy and safety of particle therapy for inoperable LA-NSCLC. Methods: To retrieve published literature, a systematic search was conducted in PubMed, Web of Science, Embase, and Cochrane Library until September 4, 2022. The primary endpoints were local control (LC) rate, overall survival (OS) rate, and progression-free survival (PFS) rate at 2 and 5 years. The secondary endpoint was treatment-related toxicity. The pooled clinical outcomes and 95% confidence intervals (CIs) were calculated by using STATA 15.1. Results: Nineteen eligible studies with a total sample size of 851 patients were included. The pooled data demonstrated that the OS, PFS, and LC rates at 2 years of LA-NSCLC treated by particle therapy were 61.3% (95% CI = 54.7-68.7%), 37.9% (95% CI = 33.8-42.6%) and 82.2% (95% CI = 78.7-85.9%), respectively. The pooled 5-year OS, PFS, and LC rates were 41.3% (95% CI = 27.1-63.1%), 25.3% (95% CI = 16.3-39.4%), and 61.5% (95% CI = 50.7-74.6%), respectively. Subgroup analysis stratified by treatment type showed that the concurrent chemoradiotherapy (CCRT, PBT combined with concurrent chemotherapy) group had better survival benefits than the PBT and CIRT groups. The incidence rates of grade 3/4 esophagitis, dermatitis, and pneumonia in LA-NSCLC patients after particle therapy were 2.6% (95% CI = 0.4-6.0%), 2.6% (95% CI = 0.5-5.7%) and 3.4% (95% CI = 1.4-6.0%), respectively. Conclusions: Particle therapy demonstrated promising efficacy and acceptable toxicity in LA-NSCLC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Efficacy and safety of proton beam therapy for rhabdomyosarcoma: a systematic review and meta-analysis.
- Author
-
Dong, Meng, Wu, Jianrong, Wu, Renhua, Wang, Dandan, Liu, Ruifeng, Luo, Hongtao, Wang, Yuhang, Chen, Junru, Ou, Yuhong, Zhang, Qiuning, and Wang, Xiaohu
- Subjects
PROTON therapy ,RHABDOMYOSARCOMA ,WEB databases ,SCIENCE databases ,PROGRESSION-free survival - Abstract
Objective: This study aimed to evaluate and conduct a meta-analysis on the efficacy and safety of proton beam therapy (PBT) for rhabdomyosarcoma (RMS). Methods: We searched for articles using PubMed, Embase, Cochrane Library, and Web of Science databases from their inception to December 22, 2022. Two researchers independently screened literature and extracted data. Statistical analyses were performed using STATA version 14.0. Results: We got 675 candidate articles, of which 11 studies were included in our study according to the inclusion and exclusion criteria. Of the 544 RMS patients who received PBT. The local control (LC) rate at 1, 2, 3, 4, and 5 years were 96% (95% confidence interval (CI) 0.91–1.01), 93% (95% CI 0.86–1.00), 78% (95% CI 0.71–0.85), 85% (95% CI 0.78–0.92), and 84% (95% CI 0.74–0.95), respectively. The progression-free survival (PFS) rate at 1, 2, 3, 4, and 5 years were 82% (95% CI 0.72–0.92), 73% (95% CI 0.61–0.84), 63% (95% CI 0.47–0.79), 64% (95% CI 0.54–0.74), and 76% (95% CI 0.59–0.94), respectively. The overall survival (OS) rate at 1, 2, 3, 4, and 5 years were 93% (95% CI 0.86–1.00), 85% (95% CI 0.76–0.95), 80% (95% CI 0.63–0.96), 71% (95% CI 0.62–0.80), and 82% (95% CI 0.71–0.94), respectively. Acute and late toxicities were mainly grades 1 to 2 in all studies. Conclusion: As an advantageous RT technique, PBT is an emerging option for patients with RMS, particularly children and adolescents patients. The data showed that PBT is a feasible, safe, and effective modality for RMS, showing promising LC, OS, PFS, and lower acute and late toxicities. PROSPERO registration number: CRD42022329154. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Charged particle therapy for high-grade gliomas in adults: a systematic review.
- Author
-
Wang, Yuhang, Liu, Ruifeng, Zhang, Qiuning, Dong, Meng, Wang, Dandan, Chen, Junru, Ou, Yuhong, Luo, Hongtao, Yang, Kehu, and Wang, Xiaohu
- Subjects
GLIOMAS ,PROTON therapy ,PARTICLE beams ,INTENSITY modulated radiotherapy ,PROTON beams - Abstract
High-grade gliomas are the most common intracranial malignancies, and their current prognosis remains poor despite standard aggressive therapy. Charged particle beams have unique physical and biological properties, especially high relative biological effectiveness (RBE) of carbon ion beam might improve the clinical treatment outcomes of malignant gliomas. We systematically reviewed the safety, efficacy, and dosimetry of carbon-ion or proton radiotherapy to treat high-grade gliomas. The protocol is detailed in the online PROSPERO database, registration No. CRD42021258495. PubMed, EMBASE, Web of Science, and The Cochrane Library databases were collected for data analysis on charged particle radiotherapy for high-grade gliomas. Until July 2022, two independent reviewers extracted data based on inclusion and exclusion criteria. Eleven articles were eligible for further analysis. Overall survival rates were marginally higher in patients with the current standard of care than those receiving concurrent intensity-modulated radiotherapy plus temozolomide. The most common side effects of carbon-ion-related therapy were grade 1–2 (such as dermatitis, headache, and alopecia). Long-term toxicities (more than three to six months) usually present as radiation necrosis; however, toxicities higher than grade 3 were not observed. Similarly, dermatitis, headache, and alopecia are among the most common acute side effects of proton therapy treatment. Despite improvement in survival rates, the method of dose-escalation using proton boost is associated with severe brain necrosis which should not be clinically underestimated. Regarding dosimetry, two studies compared proton therapy and intensity‐modulated radiation therapy plans. Proton therapy plans aimed to minimize dose exposure to non-target tissues while maintaining target coverage. The use of charged-particle radiotherapy seems to be effective with acceptable adverse effects when used either alone or as a boost. The tendency of survival outcome shows that carbon ion boost is seemingly superior to proton boost. The proton beam could provide good target coverage, and it seems to reduce dose exposure to contralateral organs at risk significantly. This can potentially reduce the treatment-related dose- and volume-related side effects in long-term survivors, such as neurocognitive impairment. High-quality randomized control trials should be conducted in the future. Moreover, Systemic therapeutic options that can be paired with charged particles are necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Does particle radiation have superior radiobiological advantages for prostate cancer cells? A systematic review of in vitro studies.
- Author
-
Du, Tian-Qi, Liu, Ruifeng, Zhang, Qiuning, Luo, Hongtao, Chen, Yanliang, Tan, Mingyu, Wang, Qian, Wu, Xun, Liu, Zhiqiang, Sun, Shilong, Yang, Kehu, Tian, Jinhui, and Wang, Xiaohu
- Subjects
PROSTATE cancer ,CANCER cells ,PHYSIOLOGICAL effects of radiation ,PARTICLE beams ,IN vitro studies - Abstract
Background: Charged particle beams from protons to carbon ions provide many significant physical benefits in radiation therapy. However, preclinical studies of charged particle therapy for prostate cancer are extremely limited. The aim of this study was to comprehensively investigate the biological effects of charged particles on prostate cancer from the perspective of in vitro studies. Methods: We conducted a systematic review by searching EMBASE (OVID), Medline (OVID), and Web of Science databases to identify the publications assessing the radiobiological effects of charged particle irradiation on prostate cancer cells. The data of relative biological effectiveness (RBE), surviving fraction (SF), standard enhancement ratio (SER) and oxygen enhancement ratio (OER) were extracted. Results: We found 12 studies met the eligible criteria. The relative biological effectiveness values of proton and carbon ion irradiation ranged from 0.94 to 1.52, and 1.67 to 3.7, respectively. Surviving fraction of 2 Gy were 0.17 ± 0.12, 0.55 ± 0.20 and 0.53 ± 0.16 in carbon ion, proton, and photon irradiation, respectively. PNKP inhibitor and gold nanoparticles were favorable sensitizing agents, while it was presented poorer performance in GANT61. The oxygen enhancement ratio values of photon and carbon ion irradiation were 2.32 ± 0.04, and 1.77 ± 0.13, respectively. Charged particle irradiation induced more G0-/G1- or G2-/M-phase arrest, more expression of γ-H2AX, more apoptosis, and lower motility and/or migration ability than photon irradiation. Conclusions: Both carbon ion and proton irradiation have advantages over photon irradiation in radiobiological effects on prostate cancer cell lines. Carbon ion irradiation seems to have further advantages over proton irradiation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico Analysis.
- Author
-
Du, Tian-Qi, Liu, Ruifeng, Zhang, Qiuning, Luo, Hongtao, Liu, Zhiqiang, Sun, Shilong, and Wang, Xiaohu
- Subjects
PROGNOSIS ,PROSTATE cancer ,GENE expression ,DNA methylation ,PROGNOSTIC models ,HISTONES - Abstract
Prostate cancer (PCa) is a type of potentially fatal malignant tumor. Immunotherapy has shown a lot of potential for various types of solid tumors, but the benefits have been less impressive in PCa. Enhancer of zeste homolog 2 (EZH2) is one of the three core subunits of the polycomb repressive complex 2 that has histone methyltransferase activity, and the immune effects of EZH2 in PCa are still unclear. The purpose of this study was to explore the potential of EZH2 as a prognostic factor and an immune therapeutic biomarker for PCa, as well as the expression pattern and biological functions. All analyses in this study were based on publicly available databases, mainly containing Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), UCSCXenaShiny, and TISIDB. We performed differential expression analysis, developed a prognostic model, and explored potential associations between EZH2 and DNA methylation modifications, tumor microenvironment (TME), immune-related genes, tumor mutation burden (TMB), tumor neoantigen burden (TNB), and representative mismatch repair (MMR) genes. We also investigated the molecular and immunological characterizations of EZH2. Finally, we predicted immunotherapeutic responses based on EZH2 expression levels. We found that EZH2 was highly expressed in PCa, was associated with a poor prognosis, and may serve as an independent prognostic factor. EZH2 expression in PCa was associated with DNA methylation modifications, TME, immune-related genes, TMB, TNB, and MMR. By gene set enrichment analysis and gene set variation analysis, we found that multiple functions and pathways related to tumorigenesis, progression, and immune activation were enriched. Finally, we inferred that immunotherapy may be more effective for PCa patients with low EZH2 expression. In conclusion, our study showed that EZH2 could be a potentially efficient predictor of prognosis and immune response in PCa patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Efficacy and safety of carbon ion radiotherapy for bone sarcomas: a systematic review and meta-analysis.
- Author
-
Dong, Meng, Liu, Ruifeng, Zhang, Qiuning, Luo, Hongtao, Wang, Dandan, Wang, Yuhang, Chen, Junru, Ou, Yuhong, and Wang, Xiaohu
- Subjects
META-analysis ,OSTEOSARCOMA ,SYSTEMATIC reviews ,BONE tumors ,CHONDROSARCOMA ,RESEARCH funding ,RADIOTHERAPY ,SARCOMA - Abstract
Objective: This study aimed to systematically evaluate and conduct a meta-analysis of the efficacy and safety of carbon ion radiotherapy for bone sarcomas.Methods: We searched for articles using the PubMed, Embase, Cochrane Library, and the Web of Science databases from their inception to January 12, 2022. Two researchers independently screened the literature and extracted data based on the inclusion and exclusion criteria. Statistical analyses were performed using STATA version 14.0.Results: We searched for 4378 candidate articles, of which 12 studies were included in our study according to the inclusion and exclusion criteria. Of the 897 BSs patients who received carbon ion radiotherapy in the studies, 526 patients had chordoma, 255 patients had chondrosarcoma, 112 patients had osteosarcoma, and 4 patients had other sarcomas. The local control rate at 1, 2, 3, 4, 5, and 10 years in these studies were 98.5% (95% confidence interval [CI] = 0.961-1.009, I2 = 0%), 85.8% (95% CI = 0.687-1.030, I2 = 91%), 86% (95% CI = 0.763-0.957, I2 = 85.3%), 91.1% (95% CI = 0.849-0.974), 74.3% (95% CI = 0.666-0.820, I2 = 85.2%), and 64.7% (95% CI = 0.451-0.843, I2 = 95.3%), respectively. The overall survival rate at 1, 2, 3, 4, 5, and 10 years in these studies were 99.9% (95% CI = 0.995-1.004, I2 = 0%), 89.6% (95% CI = 0.811-0.980, I2 = 96.6%), 85% (95% CI = 0.750-0.950, I2 = 89.4%), 92.4% (95% CI = 0.866-0.982), 72.7% (95% CI = 0.609-0.844, I2 = 95.3%), and 72.1% (95% CI = 0.661-0.781, I2 = 46.5%), respectively. Across all studies, the incidence of acute and late toxicities was mainly grade 1 to grade 2, and grade 1 to grade 3, respectively.Conclusion: As an advanced radiotherapy, carbon ion radiotherapy is promising for patients with bone sarcomas that are unresectable or residual after incomplete surgery. The data indicated that carbon ion radiotherapy was safe and effective for bone sarcomas, showing promising results for local control, overall survival, and lower acute and late toxicity.Prospero Registration Number: CRD42021258480. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
24. Analysis of the Surgical Outcomes in Elderly Patients with Hip Fractures Combined with Hemiplegia.
- Author
-
Wang, Jinqiang, Luo, Hongtao, Wang, Qi, and Zhu, Xiaohui
- Subjects
HIP fractures ,HEMIARTHROPLASTY ,OLDER patients ,HEMIPLEGIA ,LENGTH of stay in hospitals ,HEMIPLEGICS - Abstract
aimed to investigate the surgical outcomes in elderly (age ≥ 65) patients with hip fractures combined with hemiplegia and compare them with the surgical outcomes in elderly patients with hip fractures but no hemiplegia. Methods: A total of 761 elderly patients with hip fractures who were treated between January 2013 and December 2019 were enrolled in this study using a retrospective study design. The patients were divided into two groups: a hemiplegia group (77 cases, 10.1%) and a non-hemiplegia group (684 cases, 89.9%). Length of hospital stay, postoperative complications, 30-day and one-year mortalities, and one-year functional status were compared between the two groups. Results: The average length of hospital stay in the hemiplegia group (13.51 ± 10.17 days) was longer than in the non-hemiplegia group (12.60 ± 7.83 days), but the difference was not statistically significant (P = 0.354). The incidence of postoperative complications in patients with hemiplegia (28.6%, 22/77) was higher than in patients without hemiplegia (15.4%, 105/684), and the difference was statistically significant (P = 0.003). The 30-day and one-year mortalities in the hemiplegia group were higher than in the non-hemiplegia group (30 days after surgery: 10.4%, 8/77 vs 4.5%, 31/684; one year after surgery: 29.9%, 23/77 vs 15.2%, 104/684), and the difference was statistically significant (30 days after surgery: P = 0.027; one year after surgery: P = 0.001). One year after surgery, the average activity of daily living score was 56.02 ± 9.63 in the hemiplegia group and 76.89 ± 8.40 in the non-hemiplegia group, and the difference was statistically significant (P = 0.000). Conclusion: Hemiplegia can increase the incidence of postoperative complications and 30-day and one-year mortalities in patients with hip fractures. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Radiotherapy combined with surgical treatment for gastric cancer: a meta-analysis
- Author
-
Guo, Liyun, Wang, Xiaohu, Ma, Bin, Yang, Kehu, Zhang, Qiuning, Ye, Xiupeng, Luo, Hongtao, and Liu, Ruifeng
- Published
- 2011
- Full Text
- View/download PDF
26. Anti‐proliferative and metastasis‐inhibiting effect of carbon ions on non‐small cell lung adenocarcinoma A549 cells.
- Author
-
Yang, Zhen, Luo, Hongtao, Feng, Shuangwu, Geng, Yichao, Zhao, Xueshan, Li, Chengcheng, Liu, Ruifeng, Zhang, Qiuning, and Wang, Xiaohu
- Subjects
LUNG cancer ,FLOW cytometry ,CARBON ,NEUROPEPTIDES ,CANCER invasiveness ,WESTERN immunoblotting ,METASTASIS ,APOPTOSIS ,CELL cycle ,MATRIX metalloproteinases ,DOSE-response relationship (Radiation) ,CELL proliferation ,RADIATION doses ,CELL migration inhibition ,GLYCOPROTEINS ,FLUORESCENT antibody technique ,DESCRIPTIVE statistics ,RADIOTHERAPY ,CELL lines ,GLUTATHIONE peroxidase ,PHYSIOLOGICAL effects of radiation - Abstract
Objective: Carbon ions suppress the effect of glutathione peroxidase 4 (GPX4) on the proliferation and metastasis of lung adenocarcinoma A549 cells. Methods: The clonogenic formation ability of A549 cells was calculated with different ray doses of radiation. Cell proliferation, cycle, and apoptosis of A549 cells after different ray irradiation were detected by cck8 and flow cytometry. The transwell assay was used to detect the cell migration and invasion after different rays of radiation to A549 cells. The GPX4 matrix metalloproteinase 2 and E‐cadherin expression levels were assessed by immunofluorescence and western blot. Results: At the dose of 4 Gy, A549 cell viability was 22.95 ± 5.00% and 55.52 ± 3.26% when treated with carbon ions and X‐rays, respectively. The distribution of A549 cells arrested in the G2 phase by carbon ion irradiation was positively correlated with radiation dose, with a most significant increase at 4 Gy irradiation (t = 4.303, p < 0.05). The results of apoptosis after irradiation showed were no significant differences in apoptosis at 1 and 2 Gy of X‐ray compared with 0 Gy, and 4 Gy irradiation significantly induced apoptosis in A549 cells (t = 30.520, p < 0.05). The apoptotic rate of carbon ion‐irradiated cells increased in a dose‐dependent manner and was the highest at 4 Gy (t = 17.356, p < 0.05). The transwell assays showed significantly decreased migration and invasion of both ray‐irradiated cells compared with the 0 Gy control cells. The carbon ions of 2 and 4 Gy significantly inhibited A549 cell migration (t2Gy = 9.260, t4Gy = 19.052, both p < 0.05) and invasion compared with those in the control cells (t2Gy = 6.141, t4Gy = 12.700, both p < 0.05). Treatment with 2 and/or 4 Gy doses of carbon ion reduced GPX4 (t2Gy = 8.170, t4Gy = 13.811, both p < 0.05) and matrix metalloproteinase 2 (t2Gy = 207.620, t4Gy = 93.170, both p < 0.05) protein expression, but E‐cadherin expression was increased (t2Gy = 62.811, t4Gy = 102.106, both p < 0.05). Conclusion: Compared with X‐ray irradiation, carbon ions have a higher relative biological effectiveness and can increase the proportion of A549 cells arrested in the G2/M stage to induce apoptosis, thereby inhibiting proliferation. At the same dose with X‐ray, carbon ions may inhibit the migration and invasion of A549 cells by regulating the expression of GPX4, matrix metalloproteinase 2, and E‐cadherin. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Preparation of the superhydrophobic polytetrafluoroethylene (PTFE) surface by doped copper to alter microtexture characteristics.
- Author
-
Gu, Dapeng, Luo, Hongtao, Gao, Siyuan, Li, Zhi, Chen, Suwen, and Zhou, Sen
- Subjects
- *
COPPER , *POLYMERIC composites , *CONTACT angle , *SURFACE texture , *SUPERHYDROPHOBIC surfaces - Abstract
• Distribution characteristics of microscale warts are altered by doped Cu. • Superhydrophobic polytetrafluoroethylene surface obtained by filling 1–4 vol% Cu. • Water contact angle of polytetrafluoroethylene with 2.5 vol% Cu increases by 14%. A novel method for preparing the superhydrophobic polytetrafluoroethylene (PTFE) surface by doped copper (Cu) to alter microtexture (microscale warts) characteristics is proposed. Microscale warts are generated on the PTFE surface by thermal annealing. The present method achieves superhydrophobicity by adjusting Cu content to alter the morphology and distribution of microscale warts on the PTFE surface. As Cu content increases, the average area and percentage of microscale warts increase, but the density of microscale warts on the PTFE surface first increases and then decreases. An appropriate amount and size of microscale warts are obtained at 2.5 vol% Cu content. PTFE surface doped with 2.5 vol% Cu also has the best superhydrophobicity performance (water contact angle is 162.54°, water sliding angle is 5.90°). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Charged Particle Irradiation for Pancreatic Cancer: A Systematic Review of In Vitro Studies.
- Author
-
Wang, Dandan, Liu, Ruifeng, Zhang, Qiuning, Luo, Hongtao, Chen, Junru, Dong, Meng, Wang, Yuhang, Ou, Yuhong, Liu, Zhiqiang, Sun, Shilong, Yang, Kehu, Tian, Jinhui, Li, Zheng, and Wang, Xiaohu
- Subjects
PANCREATIC cancer ,PHYSIOLOGICAL effects of radiation ,IRRADIATION ,SCIENCE databases ,WEB databases - Abstract
Purpose: Given the higher precision accompanied by optimized sparing of normal tissue, charged particle therapy was thought of as a promising treatment for pancreatic cancer. However, systematic preclinical studies were scarce. We aimed to investigate the radiobiological effects of charged particle irradiation on pancreatic cancer cell lines. Methods: A systematic literature search was performed in EMBASE (OVID), Medline (OVID), and Web of Science databases. Included studies were in vitro English publications that reported the radiobiological effects of charged particle irradiation on pancreatic cancer cells. Results: Thirteen carbon ion irradiation and seven proton irradiation in vitro studies were included finally. Relative biological effectiveness (RBE) values of carbon ion irradiation and proton irradiation in different human pancreatic cancer cell lines ranged from 1.29 to 4.5, and 0.6 to 2.1, respectively. The mean of the surviving fraction of 2 Gy (SF2) of carbon ion, proton, and photon irradiation was 0.18 ± 0.11, 0.48 ± 0.11, and 0.57 ± 0.13, respectively. Carbon ion irradiation induced more G2/M arrest and a longer-lasting expression of γH2AX than photon irradiation. Combination therapies enhanced the therapeutic effects of pancreatic cell lines with a mean standard enhancement ratio (SER) of 1.66 ± 0.63 for carbon ion irradiation, 1.55 ± 0.27 for proton irradiation, and 1.52 ± 0.30 for photon irradiation. Carbon ion irradiation was more effective in suppressing the migration and invasion than photon irradiation, except for the PANC-1 cells. Conclusions: Current in vitro evidence demonstrates that, compared with photon irradiation, carbon ion irradiation offers superior radiobiological effects in the treatment of pancreatic cancer. Mechanistically, high-LET irradiation may induce complex DNA damage and ultimately promote genomic instability and cell death. Both carbon ion irradiation and proton irradiation confer similar sensitization effects in comparison with photon irradiation when combined with chemotherapy or targeted therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta‐analysis.
- Author
-
Li, Zheng, Li, Qiang, Wang, Xiaohu, Chen, Weiqiang, Jin, Xiaodong, Liu, Xinguo, Ye, Fei, Dai, Zhongying, Zheng, Xiaogang, Li, Ping, Sun, Chao, Liu, Xiongxiong, Zhang, Qiuning, Luo, Hongtao, and Liu, Ruifeng
- Subjects
CHEMOEMBOLIZATION ,HEPATOCELLULAR carcinoma ,FEVER ,COVID-19 pandemic ,OVERALL survival - Abstract
Background and aims: The existing evidence has indicated that hyperthermia ablation (HA) and HA combined with transarterial chemoembolization (HATACE) are the optimal alternative to surgical resection for patients with hepatocellular carcinoma (HCC) in the COVID‐19 crisis. However, the evidence for decision‐making is lacking in terms of comparison between HA and HATACE. Herein, a comprehensive evaluation was performed to compare the efficacy and safety of HATACE with monotherapy. Materials and Methods: Worldwide studies were collected to evaluate the HATACE regimen for HCC due to the practical need for global extrapolation of applicative population. Meta‐analyses were performed using the RevMan 5.3 software (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Results: Thirty‐six studies involving a large sample of 5036 patients were included finally. Compared with HA alone, HATACE produced the advantage of 5‐year overall survival (OS) rate (OR:1.90; 95%CI:1.46,2.46; p < 0.05) without increasing toxicity (p ≥ 0.05). Compared with TACE alone, HATACE was associated with superior 5‐year OS rate (OR:3.54; 95%CI:1.96,6.37; p < 0.05) and significantly reduced the incidences of severe liver damage (OR:0.32; 95%CI:0.11,0.96; p < 0.05) and ascites (OR:0.42; 95%CI:0.20,0.88; p < 0.05). Subgroup analysis results of small (≤3 cm) HCC revealed that there were no significant differences between the HATACE group and HA monotherapy group in regard to the OS rates (p ≥ 0.05). Conclusions: Compared with TACE alone, HATACE was more effective and safe for HCC. Compared with HA alone, HATACE was more effective for non‐small‐sized (>3 cm) HCC with comparable safety. However, the survival benefit of adjuvant TACE in HATACE regimen was not found for the patients with small (≤3 cm) HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Effect of Carbon Ion Radiation Induces Bystander Effect on Metastasis of A549 Cells and Metabonomic Correlation Analysis.
- Author
-
Yang, Zhen, Zhang, Qiuning, Luo, Hongtao, Shao, Lihua, Liu, Ruifeng, Kong, Yarong, Zhao, Xueshan, Geng, Yichao, Li, Chengcheng, and Wang, Xiaohu
- Subjects
RADIATION-induced bystander effect ,STATISTICAL correlation ,METHIONINE metabolism ,CARBON metabolism ,RADIATION ,CULTURE media (Biology) - Abstract
Objective: To analyze the effect of carbon ion (
12 C6+ ) radiation may induce bystander effect on A549 cell metastasis and metabonomics. Methods: A549 cell was irradiated with carbon ion to establish the clone survival model and the transwell matrix assay was applied to measure the effect of carbon ion on cell viability, migration, and invasion, respectively. Normal human embryonic lung fibroblasts (WI-38) were irradiated with carbon ions of 0 and 2 Gy and then transferred to A549 cell co-culture medium for 24 h. The migration and invasion of A549 cells were detected by the Transwell chamber. The analysis of metabonomic information in transfer medium by liquid phase mass spectrometry (LC-MS), The differential molecules were obtained by principal pomponent analysis (PCA) and the target proteins of significant differences (p = 1.7 × 10−3 ) obtained by combining with the STICH database. KEGG pathway was used to analyze the enrichment of the target protein pathway. Results: Compared with 0 Gy, the colony formation, migration, and invasion of A549 cells were significantly inhibited by carbon ion 2 and 4 Gy irradiation, while the inhibitory effect was not significant after 1 Gy irradiation. Compared with 0 Gy, the culture medium 24 h after carbon ion 2 Gy irradiation significantly inhibited the metastasis of tumor cells (p = 0.03). LC-MS analysis showed that 23 differential metabolites were obtained in the cell culture medium 24 h after carbon ion 0 and 2 Gy irradiation (9 up-regulated and 14 down-regulated). Among them, two were up-regulated and two down-regulated (p = 2.9 × 10−3 ). 41 target proteins were corresponding to these four differential molecules. Through the analysis of the KEGG signal pathway, it was found that these target molecules were mainly enriched in purine metabolism, tyrosine metabolism, cysteine and methionine metabolism, peroxisome, and carbon metabolism. Neuroactive ligand-receptor interaction, calcium signaling pathway, arachidonic acid metabolism, and Fc epsilon RI signaling pathway. Conclusion: The bystander effect induced by 2 Gy carbon ion radiation inhibits the metastasis of tumor cells, which indicates that carbon ions may change the metabolites of irradiated cells, so that it may indirectly affect the metabolism of tumor cell growth microenvironment, thus inhibiting the metastasis of malignant tumor cells. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
31. Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis.
- Author
-
Geng, Yichao, Zhang, Qiuning, Feng, Shuangwu, Li, Chengcheng, Wang, Lina, Zhao, Xueshan, Yang, Zhen, Li, Zheng, Luo, Hongtao, Liu, Ruifeng, Lu, Bing, and Wang, Xiaohu
- Subjects
NON-small-cell lung carcinoma ,DRUG efficacy ,CELL death ,RADIATION pneumonitis ,STEREOTACTIC radiosurgery - Abstract
Background: A combination of programmed cell death protein‐1 (PD‐1)/programmed cell death ligand‐1 (PD‐L1) inhibitors and radiotherapy (RT) is increasingly being used to treat non‐small‐cell lung cancer (NSCLC). However, the safety and efficacy of this approach remains controversial. We performed a systematic review and meta‐analysis to summarize the related research. Methods: We searched the China Biology Medicine, EMBASE, Cochrane Library, and PubMed databases for all the relevant studies. The Stata software, version 12.0 was used for the meta‐analysis. Results: The study included 20 clinical trials that enrolled 2027 patients with NSCLC. Compared with non‐combination therapy, combination therapy using PD‐1/PD‐L1 inhibitors and RT was associated with prolonged overall survival (OS) (1‐year OS: odds ratio [OR] 1.77, 95% confidence interval [CI] 1.35–2.33, p = 0.000; 2‐year OS: OR 1.77, 95% CI 1.35–2.33, p = 0.000) and progression‐free survival (PFS) (0.5‐year PFS: OR 1.83, 95% CI 1.13–2.98, p = 0.014; 1‐year PFS: OR 2.09, 95% CI 1.29–3.38, p = 0.003; 2‐year PFS: OR 2.47, 95% CI 1.13–5.37, p = 0.023). Combination therapy also improved the objective response rate (OR 2.76, 95% CI 1.06–7.19, p = 0.038) and disease control rate (OR 1.80, 95% CI 1.21–2.68, p = 0.004). This meta‐analysis showed that compared with non‐combination therapy, combination therapy using PD‐1/PD‐L1 inhibitors and RT did not increase the serious adverse event rates (≥grade 3); however, this approach increased the rate of grade 1–2 immune‐related or radiation pneumonitis. Subgroup analyses revealed that the sequence of PD‐1/PD‐L1 inhibitors followed RT outperformed in which concurrent PD‐1/PD‐L1 inhibitor and RT followed PD‐1/PD‐L1 inhibitor. Combination of stereotactic body RT or stereotactic radiosurgery with PD‐1/PD‐L1 inhibitors may be more effective than a combination of conventional RT with PD‐1/PD‐L1 inhibitors in patients with advanced NSCLC. Conclusion: Combination therapy using PD‐1/PD‐L1 inhibitors and RT may improve OS, PFS, and tumor response rates without an increase in serious adverse events in patients with advanced NSCLC. However, combination therapy was shown to increase the incidence of mild pneumonitis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Pipe Designs of the Closed Feedwater Heater Rankine Cycle Power Plant.
- Author
-
Li, Mingcheng, Luo, Hongtao, and Peng, Maolin
- Published
- 2020
- Full Text
- View/download PDF
33. Efficacy and safety of carbon‐ion radiotherapy for the malignant melanoma: A systematic review.
- Author
-
Li, Chengcheng, Zhang, Qiuning, Li, Zheng, Feng, Shuangwu, Luo, Hongtao, Liu, Ruifeng, Wang, Lina, Geng, Yichao, Zhao, Xueshan, Yang, Zhen, Li, Qiang, Yang, Kehu, and Wang, Xiaohu
- Subjects
MELANOMA ,RADIOTHERAPY safety ,META-analysis ,PROGRESSION-free survival ,COMBINATION drug therapy ,UVEAL diseases ,UVEA cancer - Abstract
Malignant melanomas (MMs) were the fifth most common cancer in men and the sixth most common cancer in women in 2018, respectively. These are characterized by high metastatic rates and poor prognoses. We systematically reviewed safety and efficacy of carbon‐ion radiotherapy (CIRT) for treating MMs. Eleven studies were eligible for review, and the data showed that MM patients showed better local control with low recurrence and mild toxicities after CIRT. Survival rates were slightly higher in patients with cutaneous or uveal MMs than in those with mucosal MMs. CIRT in combination with chemotherapy produced higher progression‐free survival rates than CIRT only. In younger patients, higher rates of distant metastases of gynecological MMs were observed. The data indicated that CIRT is effective and safe for treating MMs; however, a combination with systemic therapy is recommended to ensure the best possible prognosis for MMs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
34. Preliminary study on radiosensitivity to carbon ions in human breast cancer.
- Author
-
Zhang, Qiuning, Kong, Yarong, Yang, Zhen, Liu, Yang, Liu, Ruifeng, Geng, Yichao, Luo, Hongtao, Zhang, Hong, Li, Hongyan, Feng, Shuangwu, and Wang, Xiaohu
- Subjects
PHYSIOLOGICAL effects of carbon ,X-rays ,BREAST cancer diagnosis - Abstract
The aim of the study was to investigate the various effects of high linear energy transfer (LET) carbon ion (
12 C6+ ) and low LET X-ray radiation on MDA-MB-231 and MCF-7 human breast cancer cells and to explore the underlying mechanisms of radiation sensitivity. Cell proliferation, cell colony formation, cell cycle distribution, cell apoptosis and protein expression levels [double-strand break marker γ-H2AX, cell cycle-related protein cyclin B1, apoptosis-related proteins Bax and Bcl-2, and the Akt/mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase B1 (p70S6K) pathway] were detected after irradiation with carbon ions or X-rays at doses of 0, 2, 4 and 8 Gy. Our results showed that the inhibition of cell proliferation and cell colony formation and the induction of G2 /M phase arrest, DNA lesions and cell apoptosis/necrosis elicited by carbon ion irradiation were more potent than the effects elicited by X-ray radiation at the same dose. Simultaneously, compared with X-ray radiation, carbon ion radiation induced a marked increase in Bax and prominent decreases in cyclin B1 and Bcl-2 in a dose-dependent manner. Furthermore, the Akt/mTOR/p70S6K pathway was significantly inhibited by carbon ion radiation in both breast cancer cell lines. These results indicate that carbon ion radiation kills MDA-MB-231 and MCF-7 breast cancer cells more effectively than X-ray radiation, which might result from the inhibition of the Akt/mTOR/p70S6K pathway. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
35. Bevacizumab is an effective treatment for symptomatic cerebral necrosis after carbon ion therapy for recurrent intracranial malignant tumours: A case report.
- Author
-
Liu, Ruifeng, Luo, Hongtao, Zhang, Qiuning, Sun, Shilong, Liu, Zhiqiang, Wang, Xiaohu, Geng, Yichao, and Zhao, Xueshan
- Subjects
- *
BEVACIZUMAB , *ENDOTHELIAL growth factors , *CHONDROSARCOMA , *POSITRON emission tomography , *MAGNETIC resonance imaging , *CAVERNOUS sinus - Abstract
Carbon ion therapy (CIT) is a form of particle therapy, which not only spares normal tissues but may also improve local control of recurrent intracranial tumours. Cerebral radiation necrosis (RN) is one of the most serious adverse reactions of recurrent brain tumours following reirradiation, which may lead to neurological decline or even death. Bevacizumab is an anti-vascular endothelial growth factor antibody, which has been used to treat symptomatic RN. However, studies on bevacizumab for the treatment of CIT-induced RN are sparse. The present study described two cases that were successfully treated with bevacizumab for symptomatic RN following CIT for recurrent intracranial malignant tumours. The two recurrent intracranial malignant tumours, a chondrosarcoma in the right cavernous sinus and an anaplastic meningioma in the right frontal lobe, were enrolled in a clinical trial of CIT. Both cases were treated intravenously with bevacizumab when deterioration that appeared to be symptomatic brain RN was observed. Just before CIT, enhanced magnetic resonance imaging (MRI) was performed in each case to confirm tumour recurrence. Both cases exhibited a deterioration in symptoms, as well as on MRI, at 12-month intervals following CIT. The first case underwent positron emission tomography/computed tomography to confirm no increase in fluorodeoxyglucose uptake in lesion areas. Both cases were diagnosed as having symptomatic brain RN and began intravenous administration of four cycles of 5 mg/kg bevacizumab biweekly. The patients responded well, with rapid and marked improvements on MRI, and in clinical symptoms. No tumour progression was observed 24 months after CIT. In conclusion, bevacizumab was revealed to exert marked effects on symptomatic brain RN following CIT. Notably, cycles of bevacizumab should be administered specifically based on the aim of treating brain necrosis, and long-term or prophylactic applications are not recommended. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
36. Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of single-arm trials.
- Author
-
Liu, Ruifeng, Wei, Shihong, Zhang, Qiuning, Zhang, Xueliang, Luo, Hongtao, Tian, Jinhui, Li, Yi, Ge, Long, Wang, Xiaohu, and Roviello., Giandomenico
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.